Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009263
Filing Date
2025-05-08
Accepted
2025-05-08 16:16:04
Documents
90
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1061017
2 EX-31.1 ex31-1.htm EX-31.1 12442
3 EX-31.2 ex31-2.htm EX-31.2 18178
4 EX-32.1 ex32-1.htm EX-32.1 9738
  Complete submission text file 0001641172-25-009263.txt   7302079

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE hrow-20250331.xsd EX-101.SCH 53874
6 XBRL CALCULATION FILE hrow-20250331_cal.xml EX-101.CAL 73550
7 XBRL DEFINITION FILE hrow-20250331_def.xml EX-101.DEF 292545
8 XBRL LABEL FILE hrow-20250331_lab.xml EX-101.LAB 481726
9 XBRL PRESENTATION FILE hrow-20250331_pre.xml EX-101.PRE 411847
92 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1215144
Mailing Address 1A BURTON HILLS BLVD SUITE 200 NASHVILLE TN
Business Address 1A BURTON HILLS BLVD SUITE 200 NASHVILLE TN 615.733.4731
HARROW, INC. (Filer) CIK: 0001360214 (see all company filings)

EIN.: 450567010 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35814 | Film No.: 25926359
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)